PerkinElmer Acquires Indian IVD Firm Tulip Diagnostics
|
By LabMedica International staff writers Posted on 17 Jan 2017 |
|
PerkinElmer, Inc., which offers products, services and solutions for the diagnostics, research, environmental, industrial and laboratory services market, has entered into a definitive agreement to acquire Tulip Diagnostics Private Ltd., one of India’s largest domestic providers of in-vitro diagnostic reagents, kits and instruments.
PerkinElmer offers a global diagnostics portfolio focused on: reproductive health, infectious disease screening and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings. The company also offers instruments and services to its customers in India where it even has a laboratory for providing access to technologies that screen for and help diagnose prenatal and neonatal conditions.
Tulip’s solutions include products for the prevention, screening and diagnosis of infectious diseases such as malaria, HIV and hepatitis, and it has two manufacturing facilities located in India.
“In-vitro diagnostics is one of the fastest growing vertical segments in India, and Tulip provides the key enablers for PerkinElmer to broaden our infectious disease screening menu and capabilities for customers throughout the region,” said Jayashree Thacker, President, PerkinElmer India. “The acquisition underscores our commitment to bringing advanced healthcare innovations into India, while continuing to further expand our footprint in the country.”
“Combining our product portfolio and channel access in India with PerkinElmer’s established position as a global diagnostics provider enables us to work closely with customers in India to bring the latest infectious disease technologies to them at an affordable cost,” said Deepak Tripathi, Director and Co-founder of Tulip.
PerkinElmer offers a global diagnostics portfolio focused on: reproductive health, infectious disease screening and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings. The company also offers instruments and services to its customers in India where it even has a laboratory for providing access to technologies that screen for and help diagnose prenatal and neonatal conditions.
Tulip’s solutions include products for the prevention, screening and diagnosis of infectious diseases such as malaria, HIV and hepatitis, and it has two manufacturing facilities located in India.
“In-vitro diagnostics is one of the fastest growing vertical segments in India, and Tulip provides the key enablers for PerkinElmer to broaden our infectious disease screening menu and capabilities for customers throughout the region,” said Jayashree Thacker, President, PerkinElmer India. “The acquisition underscores our commitment to bringing advanced healthcare innovations into India, while continuing to further expand our footprint in the country.”
“Combining our product portfolio and channel access in India with PerkinElmer’s established position as a global diagnostics provider enables us to work closely with customers in India to bring the latest infectious disease technologies to them at an affordable cost,” said Deepak Tripathi, Director and Co-founder of Tulip.
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Platelet Function Analyzer
PL-12
Automatic CLIA Analyzer
Shine i6000
Latest Industry News
- Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval
- Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
- Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
- New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing
- Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing
- Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals
- Sputum-Based Lung Cancer Test Technology Granted Hong Kong Patent
- Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities
- Unilabs Expands Digital Pathology Across European Network with Proscia Platform
- Digital Pathology Partnership Integrates Breast Cancer Diagnostic and Prognostic Tools
- MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026
- Blood-Based Neurology Biomarker Assays Authorized for Use in Brazil
- Sepsis Diagnostics Market Growth Fueled by Faster Pathogen Detection Needs
- Project Advances Single-Cell Diagnostic Test for Triple-Negative Breast Cancer
- Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry
- Health Canada Licenses Point-of-Care Hematology Analyzer for Decentralized CBC Testing
Channels
Clinical Chemistry
view channel
Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more
Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more
Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read moreMolecular Diagnostics
view channel
Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease
Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more
Genomic Test Guides Extended Endocrine Therapy in Early Breast Cancer
Adjuvant endocrine therapy is standard for hormone receptor–positive early breast cancer, yet prolonged treatment brings side effects and adherence problems. Whether to continue beyond five years is a... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
HIV Monitoring Strategy Uses Drug Levels to Guide Resistance Testing
HIV viral load can rise during antiretroviral therapy for reasons that do not necessarily indicate drug resistance. Clinicians must distinguish between treatment nonadherence and resistance before deciding... Read more
Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more
Blood Biomarker May Predict Colitis Risk in Checkpoint Inhibitor Therapy
Immune checkpoint inhibitors can trigger immune-related colitis that leads to severe diarrhea, abdominal pain, and treatment interruptions. Clinicians currently lack validated tools to identify which patients... Read more
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read moreMicrobiology
view channel
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more
Pathology
view channel
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more
Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
Artera’s (Los Altos, CA, USA) multimodal artificial intelligence (MMAI) platform is being featured in five abstracts at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting.... Read more
Technology
view channel
New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more
